Switching Your Weight Loss Injection: A Guide to Moving from Wegovy or Ozempic to Zepbound

Embarking on a weight management journey with medications like Wegovy or Ozempic (semaglutide) can be a significant step towards better health. Many individuals experience success with these treatments. However, sometimes questions arise: weight loss might slow down, or curiosity builds about newer options like Zepbound (tirzepatide). The widespread discussion, sometimes dubbed the "Ozempic craze," highlights the growing interest in these therapies.¹ If contemplating a switch from semaglutide to tirzepatide, understanding the differences, potential benefits, and practical steps involved is crucial for making an informed decision in partnership with a healthcare provider.

This guide aims to provide clear, evidence-based information comparing these medications, exploring reasons for switching (like hitting a plateau), examining the potential for additional weight loss with Zepbound, outlining the typical switching process, and discussing long-term considerations.

Understanding the Key Players: Semaglutide vs. Tirzepatide

Before diving deeper, it's essential to clarify the medications involved:

• Semaglutide: This is the active ingredient in three different brand-name medications from Novo Nordisk ²:
• Wegovy: An injectable approved by the FDA specifically for chronic weight management in adults and adolescents aged 12 and older with obesity, or for adults who are overweight and have weight-related medical problems. It's also approved to reduce the risk of major cardiovascular events (like heart attack or stroke) in adults with known heart disease and either obesity or overweight.³ Wegovy should not be used concurrently with other semaglutide-containing products.⁵
• Ozempic: An injectable approved by the FDA to improve blood sugar control in adults with type 2 diabetes. It also carries approvals to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease, and recently, to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD).¹ While not FDA-approved for weight loss itself, it is frequently prescribed "off-label" for this purpose due to its known effects.¹
• Rybelsus: An oral tablet form of semaglutide, approved for improving blood sugar control in adults with type 2 diabetes.¹
• Tirzepatide: This is the active ingredient in two different brand-name medications from Eli Lilly and Company ¹⁴:
• Zepbound: An injectable approved by the FDA for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related condition. It was also recently approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.¹⁴ Zepbound should not be used with other tirzepatide products or any GLP-1 receptor agonist medicines.²³
• Mounjaro: An injectable approved by the FDA to improve blood sugar control in adults with type 2 diabetes.¹³ Like Ozempic, it's sometimes used off-label for weight loss, although Zepbound is the designated brand for this purpose.¹³

The existence of different brand names for the same active ingredient, each with specific FDA-approved uses, can be confusing. Wegovy and Zepbound are the brands specifically indicated and studied for chronic weight management. This distinction is important for understanding trial data and navigating insurance coverage. The development timeline, with tirzepatide (Mounjaro 2022, Zepbound 2023/2024) following semaglutide (Ozempic 2017, Wegovy 2021), naturally positions Zepbound as a newer alternative, prompting comparisons and interest among those seeking optimal weight loss results.³

Crucially, both Wegovy and Zepbound are intended to be used in combination with a reduced-calorie diet and increased physical activity to achieve their full benefits.⁴

How Do They Work? Understanding the Science Behind the Shots

Both semaglutide and tirzepatide belong to a class of medications known as incretin mimetics, but they work in slightly different ways.

• Semaglutide (Wegovy/Ozempic): The GLP-1 PathwaySemaglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist.2 It works by mimicking the action of a natural hormone called GLP-1, which is released by the gut in response to eating.1 By activating GLP-1 receptors in various parts of the body, semaglutide exerts several effects relevant to weight management and blood sugar control:
• Enhances Insulin Secretion: It prompts the pancreas to release more insulin, primarily when blood sugar levels are elevated after a meal. This helps lower blood sugar.²
• Reduces Glucagon Release: It decreases the release of glucagon, a hormone that signals the liver to produce sugar, further helping to control blood glucose.²
• Slows Gastric Emptying: It slows down the rate at which food leaves the stomach.² This contributes significantly to feelings of fullness and can help reduce overall food intake.
• Impacts Appetite Regulation: Semaglutide acts on GLP-1 receptors in areas of the brain, like the hypothalamus, that control appetite and satiety. This helps reduce feelings of hunger, lessen food cravings, and increase the sensation of fullness after eating.²
• Tirzepatide (Zepbound/Mounjaro): The Dual GIP and GLP-1 ActionTirzepatide takes a broader approach. It is a dual GIP and GLP-1 receptor agonist.14 This means it mimics the actions of both GLP-1 and another incretin hormone called glucose-dependent insulinotropic polypeptide (GIP). Both GIP and GLP-1 receptors are found in brain areas important for appetite regulation.31
• Tirzepatide incorporates the GLP-1 actions described above.
• In addition, it activates GIP receptors. GIP also contributes to insulin release and plays roles in energy balance, potentially influencing fat metabolism and utilization.¹⁴
• Why the Difference MattersThe activation of two distinct hormonal pathways (GIP and GLP-1) by tirzepatide, compared to the single pathway (GLP-1) activated by semaglutide, is believed to be the underlying reason for the generally greater effects on weight loss and blood sugar control observed with tirzepatide in clinical studies.32 This dual mechanism provides a plausible scientific basis for why one drug might demonstrate more pronounced results than the other. It's also worth noting that the slowed gastric emptying, a key mechanism for both drugs contributing to fullness, is also a primary reason behind common gastrointestinal side effects like nausea and vomiting.2 Understanding this connection can help anticipate and manage these potential effects.

Why Consider a Change? Common Reasons for Switching from Semaglutide

Several factors might lead someone currently using Wegovy or Ozempic to consider switching to Zepbound.

• Hitting a Weight Loss Plateau: This is perhaps the most common reason. A weight loss plateau is defined as a period where weight loss stalls or stops, despite continuing the medication and maintaining lifestyle efforts like diet and exercise.²⁸ It's important to understand that plateaus are a normal, often expected, part of the weight loss journey, not necessarily a sign that the medication has failed.⁴³ They occur due to several physiological reasons:
• Metabolic Adaptation: As weight is lost, the body's metabolism naturally slows down. It becomes more efficient at using energy, partly as a protective mechanism against perceived starvation.²⁸ A smaller body simply requires fewer calories to function at rest.²⁹
• Hormonal Adjustments: The complex interplay of hormones regulating hunger (like ghrelin) and fullness (like leptin) can shift as the body adapts to weight loss, potentially increasing appetite or making it harder to maintain a calorie deficit.²⁹
• Lifestyle Factors: Consistency is key. Slipping back into previous eating habits, reducing physical activity levels, experiencing chronic stress, getting insufficient sleep, or consuming excess alcohol can all counteract the medication's effects and contribute to a plateau.²⁷ Stress hormones like cortisol can increase cravings and slow metabolism ⁴², while poor sleep disrupts appetite-regulating hormones.⁴² Alcohol provides empty calories and can also negatively impact hunger signals.⁴⁸
• Muscle Loss: Significant weight loss can sometimes include loss of muscle mass, which further slows metabolism.²⁷ Maintaining adequate protein intake and incorporating strength training can help mitigate this.
• Medication Dose: The current dose might not be the optimal or maximum tolerated dose needed to continue driving weight loss.²⁷ Plateaus on GLP-1 medications like semaglutide often occur after a period of successful weight loss, typically estimated between 9 and 12 months ⁴⁶ or around 60 weeks of treatment.⁵² Tirzepatide plateaus might occur slightly later, perhaps around 70 weeks.⁴⁶ Experiencing a plateau can be psychologically discouraging.⁴³ Reframing it as a normal phase, and exploring strategies to overcome it – including optimizing lifestyle, adjusting dosage (if possible), or potentially switching medication – is important.²⁸
• Seeking Potentially Greater Weight Loss: Some individuals may find that semaglutide helps them lose weight, but they don't reach their personal health goals or the level of weight loss observed in clinical trial averages. Given that tirzepatide has demonstrated higher average weight loss in clinical trials, switching to Zepbound might be considered in hopes of achieving further reduction.³⁵
• Managing Side Effects: While both drugs share similar side effect profiles, particularly GI issues, individual tolerance can vary. If side effects from semaglutide are persistent and difficult to manage, discussing a switch to tirzepatide with a provider might be an option, as the body might react differently to the other active ingredient.³⁵
• Underlying Conditions: Certain conditions, notably type 2 diabetes, are associated with slightly less weight loss on these medications compared to individuals without diabetes.⁹ While both drugs are effective for weight management in this population, if results are suboptimal, a switch might be discussed.

It's crucial to recognize that if a plateau is primarily driven by drifts in diet, exercise, or other lifestyle factors, simply switching medication without addressing these underlying issues may not yield the desired results and could lead to another plateau later on.²⁷ A holistic assessment with a healthcare provider is necessary.

Zepbound vs. Semaglutide: What Does the Research Say About Weight Loss?

When considering a switch, understanding the comparative effectiveness is key. Large, randomized controlled trials (RCTs) provide the most robust evidence. The main trial programs are STEP for Wegovy (semaglutide) and SURMOUNT for Zepbound (tirzepatide).³

• Semaglutide (Wegovy) Efficacy:
• In the STEP 1 trial involving adults with overweight or obesity without diabetes, those taking Wegovy 2.4 mg once weekly for 68 weeks achieved an average weight loss of approximately 14.9%, compared to 2.4% in the placebo group.⁵⁴ A significant proportion achieved substantial weight loss: about 86% lost at least 5% of their body weight, 69% lost at least 10%, and 50% lost at least 15%.⁵⁵ Other studies confirm results around 15% average loss over 68 weeks.⁹
• For individuals with type 2 diabetes, weight loss was less pronounced but still significant. One STEP trial showed an average loss of about 10% with Wegovy versus 3% with placebo over 68 weeks.⁹ Real-world data generally aligns with trial findings.⁵³
• Tirzepatide (Zepbound) Efficacy:
• In the SURMOUNT-1 trial involving adults with overweight or obesity without diabetes, Zepbound demonstrated dose-dependent weight loss over 72 weeks. Average weight loss was approximately 16.0% for the 5 mg dose, 21.4% for the 10 mg dose, and 22.5% for the 15 mg dose, compared to 2.4% for placebo.¹⁴ At the highest dose (15 mg), 96% lost ≥5%, 90% lost ≥10%, 78% lost ≥15%, and 63% lost ≥20% of their body weight.²⁶
• In the SURMOUNT-2 trial involving adults with type 2 diabetes, average weight loss over 72 weeks was approximately 13.4% (10 mg) and 15.7% (15 mg), compared to 3.3% for placebo.³¹ Again, weight loss was substantial but less than in the non-diabetic population.³¹
• Head-to-Head Comparison (SURMOUNT-5): This trial directly compared the highest tolerated doses of Zepbound (10 mg or 15 mg) against Wegovy (1.7 mg or 2.4 mg) in adults with obesity or overweight without diabetes over 72 weeks.²³
• The results clearly favored Zepbound. Participants taking Zepbound achieved a significantly greater average weight loss of 20.2% (about 50.3 lbs or 22.8 kg) compared to 13.7% (about 33.1 lbs or 15.0 kg) for those taking Wegovy.²³ This represented a 47% greater relative weight loss with Zepbound.²³
• Furthermore, nearly twice as many participants on Zepbound achieved at least 25% weight loss compared to Wegovy (31.6% vs. 16.1%).²³
• Supporting Evidence: Meta-analyses and cohort studies consistently reinforce the finding that tirzepatide generally leads to greater average weight loss compared to semaglutide.³² One analysis calculated a mean difference favoring tirzepatide by -4.84 kg ⁶⁰, while another reported average losses of 9.7 kg for tirzepatide versus 4.81 kg for semaglutide.⁶² A real-world study observed 15% loss with tirzepatide versus 8% with semaglutide at one year.³⁸

The consistency of findings across different study types—RCTs, head-to-head trials, meta-analyses, and real-world data—strongly suggests that, on average, tirzepatide produces greater weight loss than semaglutide. This provides a solid rationale for considering a switch if maximizing weight loss is a key objective, particularly if results with semaglutide have plateaued.

While these average results are compelling, it's important to look beyond the averages. Both medications help a large proportion of users achieve clinically significant weight loss (≥5%). However, the data suggests that tirzepatide tends to enable a higher percentage of individuals to reach greater weight loss milestones (e.g., ≥15%, ≥20%, ≥25%) compared to semaglutide.²³

Table 1: Comparing Average Weight Loss: Wegovy vs. Zepbound in Key Clinical Trials

(Note: Results are averages from clinical trials; individual results will vary. H2H = Head-to-Head comparison.)

• Potential for Breaking Plateaus/Additional Loss: Based on its demonstrated higher efficacy, switching from semaglutide to tirzepatide might help some individuals break through a weight loss plateau or achieve additional weight loss.⁴² However, this is not guaranteed. Individual responses vary widely, and success still hinges on consistent lifestyle management.¹⁴

Making the Switch: A Practical Guide (Under Medical Supervision)

Switching from Wegovy or Ozempic to Zepbound is a medical decision that requires careful planning and guidance from a healthcare provider. Never attempt to switch medications or adjust dosages on your own.

• The Golden Rule: Consult Your Healthcare Provider First! This is the most critical step.³⁵ Schedule an appointment to discuss:
• Your reasons for considering a switch (plateau, efficacy goals, side effects).
• Your complete medical history, including any history of pancreatitis, gallbladder problems, kidney disease, diabetic retinopathy, depression, or personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).⁶ Zepbound and Wegovy carry a boxed warning about thyroid C-cell tumors seen in rodents and are contraindicated in those with a history of MTC or MEN 2.⁶
• All other medications currently being taken, including over-the-counter drugs and supplements. Pay special attention to other diabetes medications (like insulin or sulfonylureas) ² and oral contraceptives.¹⁴
• Your treatment goals and expectations.
• The Typical Switching Process: While the exact protocol is determined by the provider, a common approach involves:
• Stopping Semaglutide: The provider will instruct when to take the last dose of Wegovy/Ozempic.⁴¹
• Washout Period (Maybe): Some providers recommend a "washout" period of 1 to 2 weeks after stopping semaglutide before starting tirzepatide.³⁷ This allows the first drug (which has a half-life of about 7 days ⁶⁴) to clear the system, potentially reducing the risk of overlapping side effects. Other providers might transition more directly. It's essential to follow the specific instructions given. The potential variability in this step underscores why personalized medical advice is crucial.
• Starting Tirzepatide (Zepbound) Low: This is a critical safety step. Regardless of the final dose of semaglutide being taken, Zepbound is typically started at the lowest initial dose: 2.5 mg injected subcutaneously once weekly for the first 4 weeks.¹⁸ This 2.5 mg dose is intended for treatment initiation to help the body adjust and assess tolerability; it's not considered a maintenance dose for weight loss or diabetes control.¹⁶ Attempting to start at a higher dose based on previous tolerance to semaglutide can lead to significant gastrointestinal side effects.
• Gradual Dose Increase (Titration): After 4 weeks on 2.5 mg, the dose is usually increased to 5 mg once weekly. If further weight loss is needed and the medication is well-tolerated, the dose can be increased in 2.5 mg increments (to 7.5 mg, 10 mg, 12.5 mg, and up to the maximum of 15 mg once weekly for Zepbound) generally every 4 weeks.¹⁵ This titration schedule allows the body to adapt and helps manage side effects. It's important for patients switching due to a plateau to understand that reaching a potentially more effective dose of Zepbound will take several months. Managing this expectation can prevent frustration during the initial titration phase.
• Monitoring During the Switch: Close communication and follow-up appointments with the healthcare provider are necessary during the transition.³⁶ This allows for:
• Monitoring for side effects, especially GI issues like nausea, vomiting, or diarrhea.
• Assessing the body's response (changes in appetite, energy levels, early weight changes).
• Adjusting the dose titration schedule if needed (e.g., staying at a lower dose longer if side effects are problematic).
• Important Considerations During the Switch:
• Oral Contraceptives: Tirzepatide can potentially reduce the effectiveness of birth control pills because it slows stomach emptying. Women using oral contraceptives should be advised to use an additional barrier method (like condoms) or switch to a non-oral contraceptive method for 4 weeks after starting Zepbound and for 4 weeks following each dose increase.¹⁴ Semaglutide also slows gastric emptying and may affect the absorption of other oral medications.²
• Other Medications: Ensure the provider is aware of all medications. If taking insulin or sulfonylureas for diabetes, the dose of those medications may need to be lowered when starting Zepbound to reduce the risk of hypoglycemia (low blood sugar).² Blood sugar monitoring is important for those with type 2 diabetes.⁴ Tirzepatide may also affect medications with a narrow therapeutic index, like warfarin.¹⁴

The Journey Ahead: Timelines, Expectations, and Lifestyle

Managing expectations about the weight loss timeline and understanding the ongoing role of lifestyle are crucial for success when using Wegovy or Zepbound, including during a switch.

• Typical Weight Loss Timeline:
• Initial Effects: Appetite reduction is often noticeable within the first few days or weeks of starting treatment.³⁰
• Early Weight Loss: Measurable weight loss is common within the first month. For example, studies showed Wegovy users lost over 2% of body weight in the first 4 weeks.⁵²
• Gradual Progression: Weight loss typically continues gradually over many months.²⁶ Clinical trials show peak average weight loss occurring well beyond a year: around 68 weeks for Wegovy (~15% loss) ⁵² and 72 weeks for Zepbound (~21-22% loss at the highest dose).²⁶
• Plateau Phase: As discussed, weight loss often slows or stops after reaching a certain point, commonly around 60-70 weeks into treatment.⁴⁶ The weight loss journey with these medications is a marathon, not a sprint. It takes months to gradually increase the dose to the most effective level, and over a year for average weight loss to maximize in clinical trials.⁴ Patience and consistent adherence are vital.
• The Crucial Role of Lifestyle: It cannot be overstated: these medications work best as part of a comprehensive approach that includes sustained lifestyle changes.⁴ The medication helps control appetite and cravings, making it easier to adopt and stick to healthier habits, but the habits themselves drive the necessary calorie deficit and metabolic improvements. Key lifestyle components include:
• Nutrition: Following a reduced-calorie, balanced diet is fundamental.⁴ Focus on whole, nutrient-dense foods like lean proteins, vegetables, fruits, and whole grains, while limiting processed foods, added sugars, and excessive unhealthy fats.²⁷ Prioritizing protein and fiber can enhance satiety and help preserve muscle mass during weight loss.²⁷ Tracking food intake can sometimes reveal hidden calorie sources.²⁸
• Physical Activity: Regular exercise is essential for burning calories, improving metabolic health, and preserving muscle mass.⁴ Aim for at least 150 minutes of moderate-intensity aerobic activity (like brisk walking, cycling, or swimming) per week.²⁷ Incorporating strength training exercises 2-3 times per week is highly recommended to build or maintain muscle, which helps support metabolism.²⁷
• Sleep: Aim for 7-8 hours of quality sleep per night. Insufficient sleep can disrupt hunger hormones and make weight loss more difficult.²⁸
• Stress Management: Chronic stress can negatively impact weight through hormonal effects and stress-related eating.²⁸ Finding healthy coping mechanisms like mindfulness, meditation, or enjoyable hobbies is important.²⁸
• Hydration: Staying well-hydrated is important for overall health and can help manage appetite, as thirst is sometimes mistaken for hunger.²⁸
• Individual Variability: Timelines, total weight loss, and experience with side effects vary greatly from person to person.¹⁴ Factors like genetics, starting weight, adherence to medication and lifestyle changes, and the presence of other health conditions all play a role. Clinical trial results provide averages, but individual experiences may differ significantly.

Safety First: Understanding Side Effects and Risks

Both semaglutide and tirzepatide have well-documented safety profiles, including common side effects and more serious potential risks.

• Common Side Effects: The most frequently reported side effects for both medications are gastrointestinal in nature.² These include:
• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain or discomfort
• Decreased appetite (an intended effect, but can be excessive for some)
• Burping (eructation)
• Indigestion (dyspepsia)
• Gastroesophageal reflux disease (GERD) These side effects are typically mild to moderate in severity, are most common when starting the medication or increasing the dose, and often lessen over time as the body adjusts.² Strategies like slow dose titration, eating smaller meals, avoiding trigger foods, and staying hydrated can help manage them.⁴¹ Injection site reactions (like redness or itching) and fatigue have also been reported.¹⁹ Increased heart rate has been noted with Wegovy.⁵ Hair loss has been reported with Zepbound.¹⁹
• Serious Warnings and Precautions: Both classes of drugs carry warnings about potential serious risks, which should be discussed thoroughly with a healthcare provider. These include (referencing specific drug labels for complete details):
• Risk of Thyroid C-Cell Tumors (Boxed Warning): Both semaglutide and tirzepatide caused thyroid C-cell tumors in studies involving rodents. It is unknown whether they cause these tumors, including a rare type of thyroid cancer called medullary thyroid carcinoma (MTC), in humans. Due to this potential risk, these drugs should not be used by individuals with a personal or family history of MTC or by those with an endocrine condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).⁶ Any symptoms like a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath should be reported to a doctor immediately.⁶ While this warning is prominent, the actual incidence in human trials appears low, but awareness and proper patient selection are crucial.
• Acute Pancreatitis: Inflammation of the pancreas has occurred in patients taking these medications. Treatment should be stopped, and immediate medical attention sought if severe, persistent abdominal pain occurs (which may radiate to the back), with or without vomiting.⁷ A history of pancreatitis may warrant caution.⁷
• Acute Gallbladder Disease: Problems like gallstones or gallbladder inflammation can occur.¹⁴ Symptoms such as pain in the upper abdomen, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools should be reported.⁷
• Hypoglycemia (Low Blood Sugar): The risk of low blood sugar is increased, particularly when these medications are used in combination with other drugs that lower blood sugar, such as insulin or sulfonylureas.² Dose adjustments of the other diabetes medications may be necessary, and blood sugar monitoring is important for those with type 2 diabetes.
• Acute Kidney Injury: Kidney problems can develop or worsen, sometimes linked to dehydration resulting from severe nausea, vomiting, or diarrhea.² Maintaining adequate fluid intake is important.
• Hypersensitivity Reactions: Serious allergic reactions (e.g., rash, itching, swelling of face/lips/tongue, difficulty breathing, fainting) are possible and require immediate medical help.¹⁴
• Diabetic Retinopathy Complications: In patients with type 2 diabetes, existing diabetic eye disease could potentially worsen.⁷ Vision changes should be monitored.
• Suicidal Behavior and Ideation: Monitoring for depression, mood changes, or suicidal thoughts or behaviors is recommended.⁷ A history of these issues may be a reason for caution.
• Severe Gastrointestinal Disease: Patients with severe stomach problems, like gastroparesis (delayed stomach emptying), should use these drugs with caution.¹¹
• Pulmonary Aspiration Risk: Due to delayed gastric emptying, there's a potential risk of stomach contents entering the lungs during procedures requiring anesthesia or deep sedation. Healthcare providers should be informed about medication use before any planned surgery.¹¹
• Comparative Safety: Based on available clinical trial data, including the head-to-head SURMOUNT-5 trial, the overall safety profiles of tirzepatide and semaglutide appear similar.²³ Both commonly cause GI side effects. Discontinuation rates due to adverse events in major trials were relatively low, generally under 10%, but higher than placebo.²⁶
• A Note on Compounded Versions: It's important to be aware of non-FDA-approved "compounded" versions of these drugs. Regulatory bodies and experts raise concerns about the safety, efficacy, and purity of these products, as the active ingredients may not be standardized or verified.⁷² With official shortages largely resolved ⁷², the legal basis for compounding these specific drugs is diminishing, and using only FDA-approved versions prescribed by a licensed provider and obtained from a legitimate pharmacy is strongly recommended.

Keeping the Weight Off: Long-Term Maintenance Considerations

Perhaps one of the most crucial aspects to understand is that obesity is widely recognized as a chronic, relapsing disease, much like high blood pressure or type 2 diabetes.¹ This means that treatments like Wegovy and Zepbound are generally required long-term to maintain the weight loss achieved. They manage the condition but do not cure the underlying physiological factors that promote weight regain.

• Weight Regain After Stopping Medication:
• Semaglutide (Wegovy): Evidence for weight regain after stopping semaglutide is quite clear. The STEP 1 trial extension followed participants for a year after they stopped taking Wegovy (and placebo) at week 68. Those who had been on Wegovy regained, on average, two-thirds of the weight they had lost (regaining 11.6 percentage points of the initial 17.3% loss) within that year.¹ Improvements in cardiometabolic risk factors (like blood pressure and cholesterol) also tended to revert towards baseline levels after withdrawal.⁶⁸ Similarly, the STEP 4 trial demonstrated that participants switched from semaglutide to placebo after 20 weeks regained significant weight (average 6.9%), while those who continued on semaglutide lost further weight (average 7.9%) over the next 48 weeks.³ This strongly indicates that continuous treatment is necessary to maintain the benefits.
• Tirzepatide (Zepbound): While large-scale studies specifically examining weight regain after stopping tirzepatide long-term might still be emerging, the chronic nature of obesity strongly suggests that weight regain would likely occur upon discontinuation.
• Long-Term Maintenance While On Medication:
• Semaglutide (Wegovy): Long-term studies show that weight loss achieved with Wegovy can be maintained if treatment is continued. The STEP 5 trial showed sustained weight loss (average 15.2%) over a two-year period.⁶⁶ Another analysis reported sustained weight loss for up to 4 years in participants who continued treatment.⁵²
• Tirzepatide (Zepbound): Data for long-term maintenance on tirzepatide is also encouraging. The SURMOUNT-1 trial extension, the longest completed study to date, followed participants for three years (176 weeks). It showed sustained average weight loss of up to 22.9% (with the 15 mg dose) over this period.⁵⁷ A further analysis of this data found that approximately 70% of participants regained 5% or less from their lowest weight achieved (nadir) by the three-year mark, suggesting good weight stability for most while remaining on the drug.⁵⁸ Even after a 17-week off-treatment follow-up period post-trial, while some weight regain occurred (~7%) and some metabolic benefits diminished, significant net improvements compared to baseline remained.⁷⁰
• Which Drug is Better for Long-Term Maintenance?There isn't definitive head-to-head data comparing long-term maintenance after achieving maximum weight loss on both drugs. However, considering that:

1. Tirzepatide leads to significantly greater average weight loss initially.²³
2. Tirzepatide has demonstrated sustained weight loss for at least three years while on treatment ⁵⁷, with relatively limited regain from nadir for most participants during that time.⁵⁸
3. Continuous treatment is likely necessary for maintaining loss with either drug.¹ It could be inferred that tirzepatide might offer an advantage for long-term maintenance simply because individuals may be maintaining a lower overall body weight if treatment is continued consistently. Achieving a greater initial weight loss could potentially translate to greater long-term health benefits if that lower weight is successfully maintained through ongoing therapy. However, the cornerstone principle remains: long-term success with either medication hinges on continued use.

Real-World Factors: Cost, Coverage, and Final Thoughts

Beyond clinical efficacy and safety, practical considerations like cost and insurance coverage heavily influence treatment decisions.

• Cost: Wegovy and Zepbound are expensive medications. Without insurance coverage, the list price or cash price has historically been well over $1,000 per month.⁷⁶ However, recognizing the access challenges, manufacturers have introduced programs for uninsured or underinsured patients. Recent reports indicate Novo Nordisk offers Wegovy for around $499 per month via its NovoCare Pharmacy program, and Eli Lilly offers Zepbound for around $349 per month for the starter dose and $499 for higher doses through its self-pay program.⁶ While still costly, these programs represent significant reductions from list prices.
• Insurance Coverage: Coverage for medications specifically approved for weight loss is highly variable and often limited.⁴³ Many insurance plans require prior authorization, needing justification that the patient meets specific criteria before they agree to cover the cost.⁷¹ Even with commercial insurance coverage, out-of-pocket expenses can be substantial. One analysis found the average insured person taking Zepbound paid around $209 per fill in copays, potentially exceeding $2,500 annually.⁷⁷ Coverage tends to be better when these active ingredients are prescribed under their diabetes brand names (Ozempic, Mounjaro) for type 2 diabetes ⁷⁷, but this guide focuses on the Wegovy-to-Zepbound switch for weight management. It's estimated that nearly 1 in 5 people with commercial insurance have no coverage for at least one major brand-name GLP-1 agonist approved for weight loss.⁷⁷ This significant financial barrier can unfortunately override clinical considerations for many individuals.
• Savings Programs: For those with commercial insurance that does cover the medication, manufacturer savings cards (copay cards) can dramatically lower out-of-pocket costs, potentially bringing the monthly expense down to $25 or even $0 for eligible patients, although maximum annual savings caps apply.⁸ Prescription discount platforms may also offer coupons.⁷¹ Exploring these options is essential.

Table 2: Quick Glance: Wegovy vs. Zepbound Key Differences

(Note: OSA = Obstructive Sleep Apnea; CV = Cardiovascular. Costs are approximate based on recent reports and subject to change; eligibility criteria apply for programs.)

• Final Thoughts Before Deciding: The decision to switch involves weighing the potential for increased efficacy against factors like cost, insurance coverage, tolerability, and individual health circumstances. A thorough discussion with a healthcare provider is essential to navigate these factors.⁴¹

Conclusion: Is Switching to Zepbound the Right Move?

Deciding whether to switch from Wegovy or Ozempic to Zepbound for weight management is a significant consideration that depends on individual circumstances and goals.

Here's a summary of the key points:

• Different Mechanisms: Zepbound (tirzepatide) activates both GIP and GLP-1 pathways, while Wegovy/Ozempic (semaglutide) activates only the GLP-1 pathway. This dual action is thought to contribute to Zepbound's higher average efficacy.
• Higher Average Weight Loss: Clinical trials, including a direct head-to-head study (SURMOUNT-5), consistently show that Zepbound leads to greater average weight loss than Wegovy. This may make it an attractive option for those seeking to overcome a plateau on semaglutide or achieve more significant weight reduction.
• Plateaus are Normal: Weight loss plateaus are common with both medications and often result from metabolic adaptation and lifestyle factors. Switching medication is one potential strategy to address a plateau, but optimizing diet, exercise, sleep, and stress management is also crucial.
• Switching Requires Medical Guidance: Transitioning involves stopping the first medication, potentially having a washout period, and starting the new medication (Zepbound) at the lowest dose, followed by gradual titration under a provider's supervision.
• Lifestyle is Key: Success with either medication relies heavily on concurrent commitment to a reduced-calorie diet, regular physical activity, and overall healthy habits.
• Safety Profiles: Both drugs share similar common side effects (mostly GI-related) and carry important warnings, including a boxed warning regarding thyroid C-cell tumors. Individual tolerance may vary.
• Long-Term Commitment: Obesity is a chronic condition, and long-term treatment is generally necessary to maintain weight loss achieved with either Wegovy or Zepbound. Significant weight regain is expected if treatment is stopped. Zepbound's strong 3-year maintenance data (while on treatment) is promising.
• Cost and Access Barriers: These medications are expensive, and insurance coverage for weight loss is often limited, posing significant practical challenges.

Ultimately, the "best" medication is the one that is safe, effective, tolerable, and accessible for the individual patient. This guide provides information to facilitate a productive conversation with a healthcare provider. Use this knowledge to ask targeted questions about personal health status, treatment history, potential benefits and risks of switching, and navigating the practical aspects of cost and coverage. Managing weight is a personal journey, and having effective options like Wegovy and Zepbound provides more tools to help individuals find the path that best supports their long-term health and well-being.

Works cited

1. What you need to know about Ozempic and other drugs being used for weight loss, accessed April 23, 2025, https://ukhealthcare.uky.edu/wellness-community/blog/what-you-need-know-about-ozempic-and-other-drugs-being-used-weight-loss
2. Semaglutide - StatPearls - NCBI Bookshelf, accessed April 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603723/
3. Wegovy for the Treatment of Chronic Weight Management, US - Clinical Trials Arena, accessed April 23, 2025, https://www.clinicaltrialsarena.com/projects/wegovy-semaglutide-weight-management/
4. CENTER FOR DRUG EVALUATION AND RESEARCH - accessdata.fda.gov, accessed April 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215256Orig1s011.pdf
5. Wegovy (semaglutide) injection - accessdata.fda.gov, accessed April 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256Orig1s006lbl.pdf
6. Wegovy: Uses, Side Effects, Dosage, Warnings - Drugs.com, accessed April 23, 2025, https://www.drugs.com/wegovy.html
7. Wegovy (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed April 23, 2025, https://www.webmd.com/drugs/2/drug-181658/wegovy-subcutaneous/details
8. Prescription Weight Loss Medication | Wegovy® (semaglutide) Injection 2.4 mg, accessed April 23, 2025, https://www.wegovy.com/
9. Wegovy | European Medicines Agency (EMA), accessed April 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
10. FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease - Novo Nordisk, accessed April 23, 2025, https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915253
11. Ozempic (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed April 23, 2025, https://www.webmd.com/drugs/2/drug-174491/ozempic-subcutaneous/details
12. Ozempic: Cost, dosage, side effects, uses, and more - Medical News Today, accessed April 23, 2025, https://www.medicalnewstoday.com/articles/326252
13. Mounjaro for weight loss: Price, side effects, and more - Medical News Today, accessed April 23, 2025, https://www.medicalnewstoday.com/articles/drugs-mounjaro-for-weight-loss
14. Zepbound for Weight Loss: Uses, Dosage, Side Effects - Drugs.com, accessed April 23, 2025, https://www.drugs.com/zepbound.html
15. Tirzepatide: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed April 23, 2025, https://www.drugs.com/tirzepatide.html
16. Mounjaro (tirzepatide): Uses, Dosage, Side Effects & Coupons - Drugs.com, accessed April 23, 2025, https://www.drugs.com/mounjaro.html
17. Zepbound approved by FDA as first sleep apnea medication, accessed April 23, 2025, https://aasm.org/zepbound-approved-fda-first-sleep-apnea-medication/
18. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPBOUND safely and effe - accessdata.fda.gov, accessed April 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
19. FDA Approves First Medication for Obstructive Sleep Apnea, accessed April 23, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
20. Zepbound: Dosage, side effects, uses, and more - Medical News Today, accessed April 23, 2025, https://www.medicalnewstoday.com/articles/drugs-zepbound
21. FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Eli Lilly Investors, accessed April 23, 2025, https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription
22. Zepbound® (tirzepatide) Injection for Adults with Obesity or OSA, accessed April 23, 2025, https://zepbound.lilly.com/
23. Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% | Eli Lilly and Company, accessed April 23, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head
24. How to Use, Dosing & Side Effects | Mounjaro® (tirzepatide) - Eli Lilly, accessed April 23, 2025, https://mounjaro.lilly.com/how-to-use-mounjaro
25. Mounjaro® (tirzepatide) Injection: The First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes | Eli Lilly and Company, accessed April 23, 2025, https://www.lilly.com/news/media/media-kits/mounjaro
26. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight, accessed April 23, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
27. Why you're not losing weight on Zepbound? (and what to do about it) - Fay Nutrition, accessed April 23, 2025, https://www.faynutrition.com/post/why-not-losing-weight-on-zepbound-what-to-do-about-it
28. Wegovy Weight Loss Plateau: What Is it and How to Overcome It - NP2GO, accessed April 23, 2025, https://thenp2go.com/wegovy-weight-loss-plateau-what-is-it-and-how-to-overcome-it/
29. Weight Loss Plateaus on Ozempic or Mounjaro? Here's How to Break Through - REJUV, accessed April 23, 2025, https://www.rejuvcryo.com/the-science/2025/2/12/weight-loss-plateaus-on-ozempic-or-mounjaro-heres-how-to-break-through
30. Wegovy timeline: what to expect - Numan, accessed April 23, 2025, https://www.numan.com/weight-loss/medication/wegovy-timeline-what-to-expect
31. Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes, accessed April 23, 2025, https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-2-results-published-lancet-show-tirzepatide
32. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies - PubMed Central, accessed April 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11970626/
33. SURMOUNT-5: Tirzepatide Bests Semaglutide in Head-to-Head Weight Loss Trial, accessed April 23, 2025, https://www.hcplive.com/view/surmount-5-tirzepatide-best-semaglutide-in-head-to-head-weight-loss-trial
34. Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Eli Lilly, accessed April 23, 2025, https://www.lilly.com/en-CA/news/press-releases/2024.12.4-tirzepatide-surmount-5-h2h
35. Switching from Semaglutide to Tirzepatide: Is It a Good Idea? | Hubmed - HubMedEd, accessed April 23, 2025, https://www.hubmeded.com/blog/switching-from-semaglutide-to-tirzepatide-is-it-a-good-idea
36. Switching From Semaglutide To Tirzepatide: A Comprehensive Guide - Mochi Health, accessed April 23, 2025, https://joinmochi.com/blogs/switching-from-semaglutide-to-tirzepatide
37. Switching From Semaglutide To Tirzepatide Guide In 2025 - Line eraser MD, accessed April 23, 2025, https://www.lineerasermd.com/blog/switching-from-semaglutide-to-tirzepatide/
38. Tirzepatide vs. Semaglutide for Weight Loss | Ro, accessed April 23, 2025, https://ro.co/weight-loss/tirzepatide-vs-semaglutide/
39. A Comparison of Tirzepatide vs. Semaglutide From a Weight Loss Expert - NP2GO, accessed April 23, 2025, https://thenp2go.com/a-comparison-of-tirzepatide-vs-semaglutide-from-a-weight-loss-expert/
40. Comparing the Benefits of Tirzepatide vs Semaglutide for Weight Loss - BA Med Spa, accessed April 23, 2025, https://www.baweightspa.com/comparing-the-benefits-of-tirzepatide-vs-semaglutide-for-weight-loss
41. Transitioning From Wegovy To Zepbound: What Patients Should Know | Drip Hydration, accessed April 23, 2025, https://driphydration.com/blog/wegovy-to-zepbound/
42. Why Am I Not Losing Weight on Wegovy? - GoodRx, accessed April 23, 2025, https://www.goodrx.com/wegovy/why-not-losing-weight
43. If Wegovy and Zepbound Are So Effective, Why Do So Many People Stop Taking Them? | Constant Health Blog, accessed April 23, 2025, https://www.constanthealth.ca/blog/if-wegovy-and-zepbound-are-so-effective-why-do-so-many-people-stop-taking-them
44. Can I Switch From Ozempic To Wegovy For Weight Loss? - Concierge MD, accessed April 23, 2025, https://conciergemdla.com/blog/can-i-switch-from-ozempic-to-wegovy-for-weight-loss/
45. Switching From Wegovy To Zepbound: A Guide For Patients - Concierge MD, accessed April 23, 2025, https://conciergemdla.com/blog/wegovy-zepbound-switch/
46. Hitting a Weight Loss Plateau on Ozempic or Wegovy - Verywell Health, accessed April 23, 2025, https://www.verywellhealth.com/weight-loss-plateau-ozempic-wegovy-8580412
47. 7 Proven Strategies to Overcome a Weight Loss Plateau on GLP-1 Drugs, accessed April 23, 2025, https://web.stanford.edu/~kinglong/keto/7-proven-strategies-to-overcome-a-weight-loss-plateau-on-glp-1-drugs.htm
48. Ozempic Plateau: Why Am I Not Losing Weight? - HealthCentral, accessed April 23, 2025, https://www.healthcentral.com/condition/type-2-diabetes/not-losing-weight-on-semaglutide-plateau
49. Breaking Through a Weight Loss Plateau: Causes, Solutions, and Expert Tips - Ivím Health, accessed April 23, 2025, https://www.ivimhealth.com/how-to-break-a-weight-loss-plateau/
50. Why Your GLP-1 Weight Loss Might Be Plateauing - NimbleRx, accessed April 23, 2025, https://www.nimblerx.com/articles/why-your-glp-1-weight-loss-might-be-plateauing
51. How To Overcome A Weight Loss Plateau On Wegovy - UK Treated, accessed April 23, 2025, https://uk.treated.com/blog/weight-loss/preventing-plateaus-on-wegovy
52. How long do you take Wegovy for weight loss? - Medical News Today, accessed April 23, 2025, https://www.medicalnewstoday.com/articles/drugs-how-long-do-you-take-wegovy-for-weight-loss
53. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity - PMC, accessed April 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9486455/
54. Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed, accessed April 23, 2025, https://pubmed.ncbi.nlm.nih.gov/33567185/
55. STEP-1-Trial.pdf - Centre for Cardiovascular Innovation, accessed April 23, 2025, https://cci-cic.org/wp-content/uploads/2021/04/STEP-1-Trial.pdf
56. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial - ResearchGate, accessed April 23, 2025, https://www.researchgate.net/publication/350338758_Effect_of_Continued_Weekly_Subcutaneous_Semaglutide_vs_Placebo_on_Weight_Loss_Maintenance_in_Adults_With_Overweight_or_Obesity_The_STEP_4_Randomized_Clinical_Trial
57. Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks - Eli Lilly Investors, accessed April 23, 2025, https://investor.lilly.com/news-releases/news-release-details/treatment-tirzepatide-adults-pre-diabetes-and-obesity-or
58. SURMOUNT-1 trial finds tirzepatide supports long term weight control, accessed April 23, 2025, http://www.news-medical.net/news/20250411/SURMOUNT-1-trial-finds-tirzepatide-supports-long-term-weight-control.aspx
59. Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results | tctmd.com, accessed April 23, 2025, https://www.tctmd.com/news/tirzepatide-bests-semaglutide-weight-loss-surmount-5-topline-results
60. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies - PubMed, accessed April 23, 2025, https://pubmed.ncbi.nlm.nih.gov/40184508/
61. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety - PubMed, accessed April 23, 2025, https://pubmed.ncbi.nlm.nih.gov/38463003/
62. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis - PubMed, accessed April 23, 2025, https://pubmed.ncbi.nlm.nih.gov/39385875/
63. Zepbound (Tirzepatide) vs. Wegovy (Semaglutide) for Weight Loss - Verywell Health, accessed April 23, 2025, https://www.verywellhealth.com/tirzepatide-vs-semaglutide-8690775
64. Medications for Weight Loss in Adults - Gov.bc.ca, accessed April 23, 2025, https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/bc_pad_2024_medications_for_weight_loss_handout_november_2024_update.pdf
65. Do You Need to Take Wegovy Forever? Maybe, If You Want to Maintain Weight Loss, accessed April 23, 2025, https://www.goodrx.com/wegovy/how-long-wegovy-weight-loss
66. Semaglutide for weight loss: unanswered questions - Frontiers, accessed April 23, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1382814/full
67. Zepbound vs. Wegovy: Differences Between Weight-Loss Medications - GoodRx, accessed April 23, 2025, https://www.goodrx.com/conditions/weight-loss/zepbound-vs-wegovy
68. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - PubMed, accessed April 23, 2025, https://pubmed.ncbi.nlm.nih.gov/35441470/
69. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity - ABRAN, accessed April 23, 2025, http://abran.org.br/new/wp-content/uploads/2022/02/semaglutida_efeito_obesos.pdf
70. Tirzepatide shows 98.7% diabetes prevention at 3 years - Drug Discovery and Development, accessed April 23, 2025, https://www.drugdiscoverytrends.com/3-year-study-tirzepatide-prevents-diabetes-in-almost-99-of-prediabetic-adults/
71. Zepbound Vs Wegovy: Which Is Better For Weight Loss? - Klarity Health, accessed April 23, 2025, https://www.helloklarity.com/post/zepbound-vs-wegovy/
72. Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End - Pharmacy Times, accessed April 23, 2025, https://www.pharmacytimes.com/view/concerns-surrounding-compounded-glp-1s-mount-as-shortages-of-tirzepatide-semaglutide-end
73. Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance - HealthDay, accessed April 23, 2025, https://www.healthday.com/health-news/drug-center/makers-of-wegovy-zepbound-cut-prices-for-those-without-insurance
74. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, accessed April 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
75. Continuing Semaglutide Leads to Further Weight Loss - NEJM Journal Watch, accessed April 23, 2025, https://www.jwatch.org/fw117644/2021/03/23/continuing-semaglutide-leads-further-weight-loss
76. Zepbound vs Wegovy for Weight Loss - Connecticut Facial Plastic Surgery, accessed April 23, 2025, https://www.ctfacialplasticsurgery.com/blog/zepbound-vs-wegovy

Fills for Weight-Loss Medications Like Wegovy and Mounjaro Rise Despite High Out-of-Pocket Costs - GoodRx, accessed April 23, 2025, https://www.goodrx.com/healthcare-access/research/weight-loss-medication-fill-tracker